INTEGRATED BIOPHARMA INC
INBP evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for INBP—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · INBP
Integrated Biopharma Inc. is a contract manufacturer and nutraceutical company with a small cash position and ongoing clinical-stage research into traditional Chinese medicine formulations.
Key risk: Low cash runway
BioSniper Score
Based on 3 of 6 signals
Limited data coverage
Financial data as of Mar 31, 2026.
Tracking 15 clinical trials · 2 catalysts for INTEGRATED BIOPHARMA INC.
Integrated Biopharma Inc. is a contract manufacturer and nutraceutical company with a small cash position and ongoing clinical-stage research into traditional Chinese medicine formulations.
- Cash and equivalents of $5.8M as of 2026-03-31, with working capital of approximately $4.5M available under credit lines [sec_mda · as of 2026-05-08].
- Total revenue of $10.1M and net income of -$0.8M for the latest reported period as of 2026-03-31 [sec].
- Contract manufacturing segment generated $32.9M in revenue for the nine months ended March 31, 2026, with a gross profit of $0.8M [sec_mda · as of 2026-05-08].
- Other business lines (nutraceutical) contributed $1.2M in revenue for the same period, with a gross loss of $33K [sec_mda · as of 2026-05-08].
- Shareholders' equity of $20.3M and total debt of $0.1M as of 2026-03-31 [sec].
What works
- Contract manufacturing revenue remains the dominant segment, with $32.9M in the nine months ended March 31, 2026, indicating a stable core business [sec_mda · as of 2026-05-08].
- The company has minimal debt ($0.1M) and a positive shareholders' equity of $20.3M, suggesting a conservative capital structure [sec].
- Cash from operations was positive in fiscal 2025 ($2.1M) and the company maintains access to $4.5M in credit lines, providing liquidity flexibility [sec_mda · as of 2025-09-23] [sec_mda · as of 2026-05-08].
What to weigh
- Net income was negative (-$0.8M) for the latest period, and the other business lines (nutraceutical) reported a gross loss, indicating profitability challenges [sec] [sec_mda · as of 2026-05-08].
- Cash position is relatively small ($5.8M) and the company has an accumulated deficit (not explicitly stated but implied by negative net income), which may limit investment in growth or R&D [sec].
- Contract manufacturing gross profit margin declined from $3.5M in the nine months ended March 31, 2025 to $0.8M in the same period of 2026, a significant drop [sec_mda · as of 2026-05-08].
From the filings
Quoted directly from source documents.
Cash and equivalents as of March 31, 2026
“As of March 31, 2026, we had cash of $5,826”
SEC MD&A · May 8, 2026
Contract manufacturing revenue for nine months ended March 31, 2026
“Contract Manufacturing | 2026 | | $ | 26,344 | | | $ | 6,566 | | | $ | 32,910”
SEC MD&A · May 8, 2026
Net cash provided by operating activities for fiscal year 2025
“Net cash provided by operating activities | | $ | 2,065”
SEC MD&A · September 23, 2025
Other business lines gross loss for nine months ended March 31, 2026
“Other Business Lines | 2026 | | | 1,166 | | | | - | | | | 1,166 | | | | 1,199 | | | | (33”
SEC MD&A · May 8, 2026
Catalyst timeline
- 2026-09-01 · Phase 1 Start: Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients Wi — Initiation of a Phase 1 trial for a traditional Chinese medicine formula; early safety and efficacy data will be key.
- 2028-09-30 · Phase 3 Topline: Exploration of the Efficacy and Mechanism of Galantamine (an Extract From Lycoris Aurea) in Treating — Topline results from a Phase 3 study of galantamine; positive data could support regulatory filing.
Risks & what to watch (4)›
Key risks
- Low cash runway — Cash of $5.8M as of 2026-03-31 may be insufficient to fund operations and R&D if revenue declines further [sec].
- Declining contract manufacturing margins — Gross profit from contract manufacturing fell from $3.5M to $0.8M year-over-year, indicating pricing or cost pressures [sec_mda · as of 2026-05-08].
- Negative net income trend — Net loss of $0.8M in the latest period, with no clear path to profitability from current operations [sec].
- Clinical-stage uncertainty — Phase 1 and Phase 3 trials for traditional Chinese medicine formulations are early-stage and may not yield positive results [upcoming catalysts].
What to watch
- Contract manufacturing revenue and gross margin trends in upcoming quarterly reports [sec_mda · as of 2026-05-08].
- Cash burn rate and any changes in credit line usage or financing activities [sec_mda · as of 2026-05-08].
- Progress and results of the Phase 1 and Phase 3 clinical trials for Yiqi Wenyang Sanhan Formula and Galantamine [upcoming catalysts].
- Any strategic updates on the nutraceutical business line, which reported a gross loss [sec_mda · as of 2026-05-08].
Sources: SEC MD&A · Generated August 28, 2026 · How we verify sources →
Run INTEGRATED BIOPHARMA INC through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available INTEGRATED BIOPHARMA INC facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 3 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Profitable (positive operating cash flow)
D/E 0.41 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
2 upcoming, next in ~2d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Governance
Frequently asked questions
What is the AI investment thesis for INTEGRATED BIOPHARMA INC?
Integrated Biopharma Inc. is a contract manufacturer and nutraceutical company with a small cash position and ongoing clinical-stage research into traditional Chinese medicine formulations.
What is INTEGRATED BIOPHARMA INC's next catalyst?
INTEGRATED BIOPHARMA INC's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: Efficacy and Safety of Yiqi Wenyang Sanhan Formula Combined With Acupoint Application in Patients Wi" — expected September 1, 2026.
Who is the CEO of INTEGRATED BIOPHARMA INC?
Ms. Riva Kay Sheppard is the chief executive officer of INTEGRATED BIOPHARMA INC (INBP).
Where is INTEGRATED BIOPHARMA INC headquartered?
INTEGRATED BIOPHARMA INC (INBP) is headquartered in Hillside, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.